Liver Metastases of Other than Colorectal Origin
Authors:
V. Třeška; V. Liška; T. Skalický; A. Sutnar; D. Šmíd; A. Ňaršanská; M. Vachtová; Inka Třešková; J. Brůha; O. Vyčítal
Authors‘ workplace:
Chirurgická klinika FN a LF UK v Plzni, přednosta: prof. MUDr. Vladislav Třeška, DrSc.
Published in:
Rozhl. Chir., 2010, roč. 89, č. 3, s. 202-207.
Category:
Monothematic special - Original
Overview
Aim:
Colorectal carcinoma is the commonest malignancy with liver metastases. Approximately 25–30% of these metastases are resectable with good long-term outcomes. Liver metastases of so called non-colorectal carcinomas are significantly less common, and considering different biological character of these metastases, compared to colorectal ones, surgical management of some of these types is debatable, however, in some cases remains highly successful. The aim of this study was to assess the authors’ outcomes of surgical and termoablation therapy of non-colorectal liver metastases.
Methods:
The authors present their experience with surgical treatment in 68 patients – mean age of 58.2 y.o.a (33.1–77.5) with liver metastases of non-colorectal carcinomas– NKJM (the commonest types: breast carcinoma – 32.4%, carcinoid – 20.6%, renal carcinoma – 13.3%, gynecological tumors – 13.3%, gastrointestinal stromal tumor – 4.4%, gastric carcinoma – 4.4% ) during 2001–2008. The mean time after primary surgery for carcinoma was 3.9 years (0–8.5 let). The surgical procedures included the following: radiofrequency ablation (RFA) – 50 patients (73.5%), resections in 26.5%. Preoperative chemotherapeutical „downstaging“ or portal vein embolization on the tumor side, in order to improve the NKJM resecability, was performed in 10 subjects (14.7%). Resecable or RFA – manageable extrahepatic metastases were removed using one- or more- step procedures in 25 subjects (36.7%). The total number of liver metastases within the whole study group ranged from 1 (28x) to 8 (1x) metastases. Postoperative adjuvant chemotherapy, combined with biological treatment in some patients, was administered to a total of 33 patients (48.5%).
Results:
One year after the procedure and RFA, a total of 88.6% of patients were surviving, at 3 years 72.5 % and at 5 years 36.9% of the subjects. Considering four commonest tumors (breast carcinoma, carcinoid, gynecological carcinomas and renal carcinoma), the best 5-year survival rates were recorded in patients with carcinoid metastases (100%), 33.8% of patients with breast metastases were surviving at 5 years, 44.4% of patients with renal carcinoma metastases were surviving at 3 years and 72.9% of patients with gynecological tumors were surviving at 2 years. There were no statistically significant differences in long-term survival rates between RFA and resections. Patients with extrahepatic metastases had worse prognosis (p < 0.01).
Conclusion:
Liver resection and RFA have their definite place in multimodal treatment strategy in the management of non- colorectal carcinoma liver metastases (NKJM). Indication for surgery must be made on strictly individual basis, in particular in patients with NKJM, in order to achieve quality long-term survival in these patients.
Key words:
non-colorectal carcinoma liver metastases – radiofrequency ablation – resection – long-term outcomes
Sources
1. Shah, S. A., Bromberg, R., Coates A. Survival after liver resection for metastatic colorectal carcinoma in a large population. J. Am. Coll. Surg., 2007; 205: 676–683.
2. Choi, E. U., Abdalla, E. K. Patient selection and outcome of hepatectomy for noncolorectal non-neuroendocrine liver metastases. Surg. Oncol. Clin. N. Am., 2007; 16: 557–577.
3. O‘Rourke, T. R., Tekkis, P., Yeung, S., Fawcett, J., Lynch,S., Strong, R., Wall, D., John, T. G., Welsh, F., Rees, M. Long-term results of liver resection for non-colorectal, non-neuroendocrine metastases. Ann. Surg. Oncol., 2008; 15: 207–218.
4. Laurent, Ch., Rullier, E., Feyler, A., Masson, B., Saric, J. Resection of noncolorectal and nonneurocrine liver metastases: late metastases are the only chance of cure. World J. Surg., 2001; 25: 1532–1536.
5. Dejong, C. H. C., Parks, R. W., Currie, E., Piris, J., Redhead, D. N., Garden, O. J. Treatment of hepatic metastases of neuroendocrine malignancies: a 10-year experience. J. R. Coll. Surg. Edinb., 2002; 47: 495–499.
6. Strosberg, J. R., Choi, J., Cantor, A. B., Kvols, L. K. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control, 2006; 13: 72–78.
7. Hodul, P., Malafa, M., Choi, J., Kvols, L. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control, 2006; 13: 61–71.
8. Martinez, S. R., Young, S. E.,Giuliano, A. E., Bilchik, A. J. The utility of estrogen receptor, progesterone receptor, and Her-2/ n status to predict survival in patients undergoing hepatic resection for breast cancer metastases. Am. J. Surg., 2006; 191: 281–283.
9. Adam,R., Aloia, T., Krissat, J., Bralet, M. P., Paule, B., Giacchetti, S., Delvart, V., Azoulay, D., Bismuth, H., Castaing, D. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann. Surg., 2006; 244: 897–908.
10. Caralt, M., Bilbao, I., Cortés, J., Escartin, A. Lázaro, J. L.,Dopazo, C., Olsina, J. J., Balsells, J., Charco, R. Hepatic resection for liver metastases as part of the „oncosurgical“ treatment of metastatic breast cancer. Ann. Surg. Oncol., 2008; 15: 2804–2810.
11. Furka, A., Halász, L., Szentkereszty, Z., Pósán, J., András, C., Sápy, P. Surgical treatment of liver metastases from breast cancer. Hepato-Gastroenterology, 2008; 55: 1416–1418.
12. Thelen, A., Jonas, S., Benckert, C., Lopez-Hanninen, E., Rudolph, B., Neumann, U., Neuhaus, P. Liver resection for metastases from renal cell carcinoma. World J. Surg., 2007; 31: 802–807.
13. Alves, A., Adam, R., Majno, P., Delvart, V., Azoulay, D., Castaing, D., Bismuth, A. Hepatic resection for metastatic renal tumors: Is it worthwhile? Ann. Surg. Oncol., 2003; 10: 705–710.
14. Chi, D. S., McCaughty, K., Diaz, J. P. Guidelines and selection criteria for secondary cytoreductive Sumery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer, 2006; 106: 1933–1999.
15. Rose, D. M., Essner, R., Hughes, T. M. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch. Surg., 2001; 136: 950–955.
16. Pohnán, R., Ryska, M., Doležel, R., Veverová, I., Linke, Z. Gastrointestinální stromální tumor- analýza vlastní sestavy pacientů, přehled literatury. Rozhl. Chir., 2009; 88: 629–633.
17. Yamada, S., Fujii, T., Sugimoto, H., Kanazumi, N., Kasuya, H., Nomoto, S., Takeda, S., Kodera, Y., Nakao, A. Pancreatic cancer with distant metastases: A contraindication for radical surgery? Hepato-Gastroenterology, 2009; 56: 881–885.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2010 Issue 3
Most read in this issue
- Liver Metastases of Other than Colorectal Origin
- Modern Algorithms for Diagnostics and Treatment of Anorectal Fistulas in Clinical Practice– Case Reviews
- Iatrogenic Bile Ducts Injuries
- Gastric Carcinoma and Current Situation